Comparison · NCT02827500-dc8cf236
Pre-discharge Ivabradine vs Usual Care: Number of Participants Taking Ivabradine at 180 Days
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pre-discharge Ivabradine vs Usual Care: Number of Participants Taking Ivabradine at 180 Days. Trial comparisons, record NCT02827500-dc8cf236. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02827500-dc8cf236
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.404 | 0.282 | 0.539 | wilson | |
| Risk in group 2 | 0.115 | 0.054 | 0.23 | wilson | |
| Risk difference, group 1 minus group 2 | 0.288 | 0.121 | 0.437 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.5 | 1.54 | 7.96 | log | |
| Odds ratio, group 1 over group 2 | 5.19 | 1.88 | 14.3 | log | |
| Number needed to treat, for one more participant with the outcome on Pre-discharge Ivabradine than on Usual Care | 3.47 | 2.29 | 8.26 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: usual care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pre-discharge Ivabradine | Active Comparator: ivabradine~ivabradine: Active Comparator: ivabradine | 21 | 52 | OG001 |
| Group 2 | Usual Care | Placebo Comparator: usual care~Usual Care: Placebo Comparator: usual care | 6 | 52 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Taking Ivabradine at 180 Days
- Description
- Time frame
- 180 days
- Population
- Intent to treat population
Source ClinicalTrials.gov
Trial
- Title
- Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
- NCT number
- NCT02827500
- Phases
- PHASE4
- Conditions
- Heart Failure
- Interventions
- ivabradine, Usual Care
- Lead sponsor
- Duke University
- Results first posted
- 2019-10-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02827500?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02827500-dc8cf236